Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt D, Takimoto SM, Aisner DL, Wilhelm F, Frederick BA, Varella-Garcia M, Tan AC, Jimeno A. Anderson RT, et al. Among authors: bowles dw. Mol Cancer Ther. 2013 Oct;12(10):1994-2005. doi: 10.1158/1535-7163.MCT-13-0206. Epub 2013 Jul 19. Mol Cancer Ther. 2013. PMID: 23873848 Free PMC article.
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. Hong DS, et al. Among authors: bowles dw. Clin Cancer Res. 2012 Aug 1;18(15):4173-82. doi: 10.1158/1078-0432.CCR-12-0714. Epub 2012 Jun 12. Clin Cancer Res. 2012. PMID: 22693357 Clinical Trial.
Vismodegib in basal cell carcinoma.
Amaria RN, Bowles DW, Lewis KD, Jimeno A. Amaria RN, et al. Among authors: bowles dw. Drugs Today (Barc). 2012 Jul;48(7):459-67. doi: 10.1358/dot.2012.48.7.1808490. Drugs Today (Barc). 2012. PMID: 22844657 Review.
Axitinib, a new therapeutic option in renal cell carcinoma.
Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Kessler ER, et al. Among authors: bowles dw. Drugs Today (Barc). 2012 Oct;48(10):633-44. doi: 10.1358/dot.2012.48.10.1860768. Drugs Today (Barc). 2012. PMID: 23110259 Review.
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A. Keysar SB, et al. Among authors: bowles dw. Cancer Res. 2013 Jun 1;73(11):3381-92. doi: 10.1158/0008-5472.CAN-12-4047. Epub 2013 Apr 10. Cancer Res. 2013. PMID: 23576557 Free PMC article.
107 results